S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:PHAS

PhaseBio Pharmaceuticals - PHAS Stock Forecast, Price & News

$0.05
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.04
$0.78
52-Week Range
$0.07
$4.08
Volume
141,787 shs
Average Volume
848,888 shs
Market Capitalization
$2.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

PhaseBio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
8,990.9% Upside
$4.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$267,616 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

PHAS stock logo

About PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

PhaseBio Files for Bankruptcy With Plans to Sell Assets
See More Headlines
Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Company Calendar

Last Earnings
11/10/2021
Today
12/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAS
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+8,990.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-131,070,000.00
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%

Debt

Sales & Book Value

Annual Sales
$10.83 million
Book Value
($1.93) per share

Miscellaneous

Free Float
44,922,000
Market Cap
$2.47 million
Optionable
Not Optionable
Beta
2.57

Key Executives

  • Jonathan P. Mow
    Chief Executive Officer & Director
  • John P. Sharp
    Chief Financial Officer
  • John S. Lee
    Chief Medical Officer
  • Kristopher L. Hanson
    Secretary, Senior VP & General Counsel
  • Susan E. Arnold
    Senior Vice President-Technical Operations













PHAS Stock - Frequently Asked Questions

Should I buy or sell PhaseBio Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares.
View PHAS analyst ratings
or view top-rated stocks.

What is PhaseBio Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued twelve-month price targets for PhaseBio Pharmaceuticals' shares. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they expect the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 8,990.9% from the stock's current price.
View analysts price targets for PHAS
or view top-rated stocks among Wall Street analysts.

How have PHAS shares performed in 2022?

PhaseBio Pharmaceuticals' stock was trading at $2.61 at the start of the year. Since then, PHAS stock has decreased by 98.1% and is now trading at $0.0495.
View the best growth stocks for 2022 here
.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The firm earned $0.34 million during the quarter, compared to analysts' expectations of $2.67 million.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Resources Investment Advisors LLC. (0.34%). Insiders that own company stock include Clay Thorp, Edmund Harrigan, Enterprise Associates 13 L New and Glen Burkhardt.
View institutional ownership trends
.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $0.05.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $2.47 million and generates $10.83 million in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com.

This page (NASDAQ:PHAS) was last updated on 12/3/2022 by MarketBeat.com Staff